Hymenoptera venoms are known to cause life-threatening IgE-mediated anaphylactic reactions in allergic individuals. Venom immunotherapy is a recommended treatment of insect allergy with still the mechanism not being completely understood. We decided to assess the serum CCL5/RANTES level in patients who experienced severe anaphylactic reaction to Hymenoptera venom and to find out changes in the course of immunotherapy. Twenty patients (9 men, 11 women, mean age: 31.91 ± 7.63 years) with history of anaphylactic reaction after insect sting were included into the study. Diagnosis was made according to sIgE and skin tests. All of them were enrolled into rush venom immunotherapy with bee or wasp venom extracts (Pharmalgen, ALK-Abello, Horsholm, Denmark). Serum levels of CCL5/RANTES were measured using a commercially available ELISA kit (R&D Systems, Minneapolis, MN). CCL5/RANTES serum concentration are higher in insect venom allergic patients than in healthy controls (887.5 ± 322.77 versus 387.27 ± 85.11 pg/ml). Serum concentration of CCL5/RANTES in insect venom allergic patient was significantly reduced in the course of allergen immunotherapy already after 6 days of vaccination (887.5 ± 322.77 versus 567.32 ± 92.16 pg/ml). CCL5/RANTES serum doesn't correlate with specific IgE. Chemokine CCL5/RANTES participates in allergic inflammation induced by Hymenoptera venom allergens. Specific immunotherapy reduces chemokine CCL5/RANTES serum level already after initial days of venom immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/08923973.2015.1063645 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pathogenic and Nonpathogenic Antibody Responses in Allergic Diseases.
Eur J Immunol
March 2025
Institut Pasteur, Université de Paris Cité, Unit of Antibodies in Therapy and Pathology, Paris, France.
Allergen-specific antibodies, particularly of the IgE class, are a hallmark of many allergic diseases. Yet paradoxically, (1) a proportion of healthy individuals possess allergen-specific IgE without clinical signs of allergy; (2) some, but not all, allergic individuals develop a more severe disease over time or fail to respond to allergen-specific immunotherapy; and (3) allergen-specific IgG antibodies can inhibit IgE-mediated responses but they can also induce allergic reactions. In this review, we discuss the occurrence of and transition between nonpathogenic and pathogenic allergen-specific antibody responses in the light of a two-stage model.
View Article and Find Full Text PDFAllergen Immunotherapy in Autoimmune Terrain: A Case Study.
Indian J Otolaryngol Head Neck Surg
January 2025
Department of Endocrinology, Joshi Clinic, Mumbai, India.
Allergen immunotherapy (AIT), or specific immunotherapy (SIT), is an effective treatment for inducing immune tolerance to specific allergens. It is widely used for allergic rhinitis, conjunctivitis, asthma, and Hymenoptera venom allergies, with recent applications to food allergies and atopic dermatitis. Despite its benefits, the use of SIT in patients with autoimmune diseases is controversial due to concerns about its potential to induce or exacerbate autoimmune conditions.
View Article and Find Full Text PDFPattern of sensitization to yellow jacket venom and expression of recombinant antigen 5 (Ves v 5) from yellow jacket venom.
BMC Immunol
March 2025
Department of Immunology, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
Background: Hymenoptera venom allergy is a significant allergic reaction that affects a substantial proportion of adults. Accurate diagnosis of this allergy using venom extracts is challenging due to molecular cross-reactivity. Pure recombinant allergens offer a promising solution to identify the specific venom responsible for allergic reactions.
View Article and Find Full Text PDFVenom Allergen Immunotherapy in Children: Short-term Efficacy and Impact on Quality of Life.
Ann Allergy Asthma Immunol
March 2025
Pediatric Allergy Department, Hacettepe University School of Medicine, Ankara, Turkey. Electronic address:
Background: Hymenoptera venom allergy (HVA) is a potentially life-threatening reaction to stings from Apis mellifera (honeybee) or Vespula (yellowjacket).
Objective: We aimed to evaluate re-sting reactions during or after venom immunotherapy (VIT) and the impact of VIT on the quality of life (QoL) of children with HVA.
Methods: Seventy-eight patients who experienced grade 3, 4, or 5 systemic reactions and underwent conventional subcutaneous VIT were included.
Melittin, A Potential Game-changer in the Fight Against Breast Cancer: A Systematic Review.
Anticancer Agents Med Chem
February 2025
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States.
Introduction: Breast cancer is the most common cancer in women. Traditional treatments include endocrine therapy, chemotherapy, surgery, radiation, and immunotherapy. Recent studies suggest melittin, a component of bee venom, as a promising breast cancer treatment due to its anticancer properties: inducing cytotoxicity, apoptosis, and gene regulation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!